

Ludwig Scientist (s)	Affiliation (s)	Session Time	Location	Track/Category	Subcategory	Session Type	Session Title	Presentation/Abstract Title + Time
Friday, May 29, 2015								
Peter Gibbs	Ludwig Melbourne	1:00 PM - 2:15 PM	S404	Tumor Biology Value; Cancer Prevention, Genetics, and Epidemiology; Health Services Research and Quality of Care		Education Session	Early Detection of Cancer: Past, Present, and Future	No abstract 1:40 PM - 2:00 PM Detection of Circulating Tumor Cells and Circulating Tumor DNA
Saturday, May 30, 2015								
Bert Vogelstein, Luis Diaz**	Ludwig Johns Hopkins	8:00 AM - 9:30 AM	E Hall D1	Gastrointestinal (Colorectal) Cancer	Colorectal Cancer	Clinical Science Symposium	Immunotherapy for Every Patient: Check Your Enthusiasm	LATE BREAKING ABSTRACT: #LBA100 PD-1 blockade in tumors with mismatch repair deficiency.
Margaret Callahan, Andrew J. Park, Linda Pan, Ralph Venhaus, Stephen Hodi, Jedd Wolchok**	Ludwig New York Ludwig Harvard Ludwig MSK	8:00 AM - 11:30 AM	S Hall A Poster Board #419a	Developmental Therapeutics—Immunotherapy	Immunotherapy and Biologic Therapy	Poster Session	Developmental Therapeutics – Immunotherapy	TRIAL IN PROGRESS: Abstract #TPS3099 A phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
George Coukos*	Ludwig Lausanne	1:15 PM - 4:45 PM	S Hall A Poster Board #77	Gynecologic Cancer	Ovarian Cancer	Poster Session	Gynecologic Cancer	Abstract #5519: Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade to elicit antitumor immune response in ovarian cancer.
Stephen Hodi*, Jedd Wolchok**	Ludwig Harvard Ludwig MSK	1:15 PM - 4:15 PM	E354b	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Oral Abstract Session	Melanoma/Skin Cancers	Abstract #9004 2:27 PM - 2:39 PM Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
Peter Gibbs*	Ludwig Melbourne	3:00 PM - 6:00 PM	E Hall D2	Gastrointestinal (Colorectal) Cancer	Colorectal Cancer	Oral Abstract Session	Gastrointestinal (Colorectal) Cancer	Abstract #3502 3:24 PM - 3:36 PM SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
George Coukos**	Ludwig Lausanne	4:45 PM - 6:00 PM	E354b	Gynecologic Cancer	Ovarian Cancer	Poster Discussion Session	Gynecologic Cancer	Abstract #5519: Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade to elicit antitumor immune response in ovarian cancer.
Sunday, May 31, 2015								
Max Diehn, Ash Alizadeh**	Ludwig Stanford	8:00 AM - 11:30 AM	S Hall A Poster Board #388	Lymphoma and Plasma Cell Disorders	Lymphoma	Poster Session	Lymphoma and Plasma Cell Disorders	Abstract #8570: Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
Max Diehn, Ash Alizadeh**	Ludwig Stanford	8:00 AM - 11:30 AM	S Hall A Poster Board #356	Lymphoma and Plasma Cell Disorders	Lymphoma	Poster Session	Lymphoma and Plasma Cell Disorders	Abstract #8539: Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).
Tom John**	Ludwig Melbourne	8:00 AM - 11:30 AM	S Hall A Poster Board #264	Immunobiology	Tumor Biology	Poster Session	Tumor Biology	Abstract #11051: Prognostic significance of stromal versus intratumoral infiltrating CD8+ lymphocytes in resected non-small cell lung cancer.

*denotes scientist is first author

**denotes scientist is last author

Andrew Wagner*	Ludwig Harvard	8:00 AM - 11:30 AM	S Hall A Poster Board #208	Sarcoma	Soft Tissue	Poster Session	Sarcoma	Abstract #10564: A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.
Jedd Wolchok*, Stephen Hodi**	Ludwig MSK Ludwig Harvard	1:00 PM - 4:00 PM	N Hall B1	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Plenary Session	Plenary Session Including the Science of Oncology Award and Lecture	LATE-BREAKING ABSTRACT: #LBA1 1:35 PM - 1:50 PM Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).
Jedd Wolchok	Ludwig MSK	4:00 PM - 4:30 PM	S100bc			Scientific Special Session	Post-Plenary Discussion I: Melanoma/Skin Cancers	No abstract
Monday, June 1, 2015								
Peter Gibbs**	Ludwig Melbourne	8:00 AM - 11:30 AM	S Hall A Poster Board #49	Gastrointestinal (Colorectal) Cancer	Colorectal Cancer	Poster Session	Gastrointestinal (Colorectal) Cancer	Abstract #3557: Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer.
Taha Merghoub, Margaret Callahan, Jedd Wolchok, Michael Andrew Postow**	Ludwig MSK	1:15 PM - 4:45 PM	S Hall A Poster Board #318	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Poster Session	Melanoma/Skin Cancers	Abstract #9075: Investigation of inpatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab.
Jonathan Cebon, Stephen Hodi**	Ludwig Melbourne Ludwig Harvard	1:15 PM - 4:45 PM	S Hall A Poster Board #323a	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Poster Session	Melanoma/Skin Cancers	TRIAL IN PROGRESS: Abstract #TPS9081 A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.
Jonathan Cebon	Ludwig Melbourne	1:15 PM - 4:15 PM	S406	Developmental Therapeutics and Translational Research		Oral Abstract Session	Developmental Therapeutics—Immunotherapy	No abstract 1:51 PM - 2:03 PM The Role of the Microenvironment in Response Prediction
Jedd Wolchok*, Stephen Hodi**	Ludwig New York Ludwig Harvard	1:15 PM - 4:15 PM	S406	Developmental Therapeutics—Immunotherapy	Immunotherapy and Biologic Therapy	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	Abstract #3000 1:15 PM - 1:27 PM Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.
Hui Gan, Andrew J. Park, Linda Pan, Ralph Venhaus**	Ludwig Melbourne Ludwig New York	1:15 PM - 4:45 PM	S Hall A Poster Board: #66b	Central Nervous System Tumors	Central Nervous System Tumors	Poster Session	Central Nervous System Tumors	TRIAL IN PROGRESS: Abstract #TPS2077 Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). No presentation.
Prashanth Prithviraj*, Sagun Parakh, Jonathan S. Cebon	Ludwig Melbourne	1:15 PM to 4:45 PM	S Hall A Poster Board #302	Melanoma/Skin Cancers	Melanoma/Skin Cancers	Poster Session	Melanoma/Skin Cancers	Abstract #9059: Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy.
George Demetri*	Ludwig Harvard	3:00 PM - 6:00 PM	S504	Sarcoma	Sarcoma	Oral Abstract Session	Sarcoma	Abstract #10503 4:00 PM - 4:12 PM A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).
Stephen Hodi	Ludwig Harvard	4:45 PM - 6:00 PM	S406	Patient and Survivor Care Practice; Developmental Therapeutics and Translational Research		Education Session	The ABCs of Cancer Immunotherapy	No abstract 4:45 PM - 5:05 PM How to Interpret Antitumor Response in Immunotherapy
Hui Gan*, Andrew Scott	Ludwig Melbourne	4:45 PM - 6:00 PM	S100a	Central Nervous System Tumors	Central Nervous System Tumors	Poster Discussion Session	Central Nervous System Tumors	Abstract #2016: Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).

*denotes scientist is first author

**denotes scientist is last author

Publication-only abstracts: published in conjunction with the 2015 ASCO Annual Meeting but not presented at the Meeting. Can be found online only.							
Jeanne Tie, Ben Tran, Peter Gibbs**	Ludwig Melbourne		http://abstracts.asco.org/156/AbstView_156_151297.html	Gastrointestinal (Colorectal) Cancer	Colorectal Cancer		Abstract #e14648: Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia.
Jonathan Fletcher**	Ludwig Harvard		http://abstracts.asco.org/156/AbstView_156_144512.html	Sarcoma	Soft Tissue		Abstract #e21512: The role of AURKA in liposarcoma.
Geoffrey Greene**	Ludwig Chicago		http://abstracts.asco.org/156/AbstView_156_144420.html	Breast Cancer—HER2/ER	ER+		Abstract #e11514: Relationship of progesterin receptor to estrogen receptor and the relevance of the progesterin receptor in predicting survival in breast cancer.

*denotes scientist is first author

**denotes scientist is last author